Biomet acquires anticoagulant specialist
This article was originally published in Clinica
Orthopaedics firm Biomet has bought anticoagulant maker Cytosol Laboratories in order to secure a critical supply for its platelet separation and concentration technology. Cytosol was founded in 1968 and develops three proprietary anticoagulants to aid in the processing of blood components. It markets noClot-50; TriCitrasol, which is used for anticoagulation during granulocytapheresis; and Rejuvesol, which rejuvenates stored, frozen red blood cells prior to transfusion. Biomet (Warsaw, Indiana) said that the anticoagulants would be used in its GPS III platelet separation system and BioCue platelet concentration system, which are used to concentrate and mix a combination of blood and bone marrow. Biomet secured all of the assets of the Braintree, Massachusetts firm for an undisclosed fee.